Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales

Mohammad Shehab,Talat Bessissow

DOI: https://doi.org/10.1111/apt.18269

IF: 9.524

2024-09-20

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Solitano et al papers. To view these articles, visit https://doi.org/10.1111/apt.18210 and https://doi.org/10.1111/apt.18288

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Performance of bowel preparation quality scales in patients with Crohn's disease

Virginia Solitano,Corey A Siegel,Joshua R Korzenik,Jennifer K Maratt,Douglas K Rex,Bryan Maguire,Brian Bressler,Johannes Grossmann,Rocio Sedano,John W D McDonald,Julie Remillard,Lisa M Shackelton,Guangyong Zou,Brian G Feagan,Christopher Ma,Vipul Jairath

DOI: https://doi.org/10.1111/apt.18210

Abstract:Background: The performance of bowel preparation (BP) in patients with Crohn's disease (CD) is unknown. Aims: To evaluate the operating properties of instruments used to assess BP quality in patients with CD. Methods: We used the Boston Bowel Preparation Scale, modified Boston Bowel Preparation Scale, Harefield Cleansing Scale, Food and Drug Administration Bowel Cleansing Assessment Scale (BCAS), and a 100-mm visual analogue scale of bowel cleanliness to assess BP quality in 50 videos from 40 patients with CD. We assessed endoscopic activity with the Simple Endoscopic Score for CD (SES-CD). Assessments were on endoscope insertion and withdrawal. Reliability was quantified using the intraclass correlation coefficient (ICC). We assessed validity by within-patient correlation between instruments and the visual analogue scale using mixed-effect models. The correlation between BP quality and SES-SD scores was assessed using Spearman's rho. Results: Inter- and intra-rater reliability for all BP quality instruments was substantial (ICC ≥0.61) except for the Food and Drug Administration BCAS on insertion (inter-rater reliability ICC ≥0.41). The visual analogue scale had substantial inter- and almost perfect (ICC ≥0.81) intra-rater reliability. Correlation coefficients for the validity of the instruments exceeded 0.58. BP quality and endoscopic disease activity scores in the colon were negatively correlated. Conclusion: Most existing instruments reliably assess BP quality in patients with CD. These results support the use of these instruments in clinical practice, provide a framework for scoring BP quality in CD clinical trials, and support evaluation of novel BP agents in patients with CD.
P477 Performance of bowel preparation quality scales in patients with Crohn’s disease

V Solitano,C A Siegel,J R Korzenik,J K Maratt,D K Rex,B Maguire,B Bressler,J Grossmann,J W D McDonald,J Remillard,L M Shackelton,B G Feagan,C Ma,V Jairath

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0607

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background The performance of bowel preparation (BP) in patients with Crohn’s disease (CD) is unknown and may be suboptimal due to the presence of mucosal inflammation, strictures, pseudopolyps and bowel resection. We evaluated the reliability and validity of available BP scales in patients with CD. Methods Bowel preparation, in colonoscopy videos (N=50) from patients with CD (N=40) that represented a range of bowel preparation quality and endoscopic disease activity, was independently rated twice, separated by at least 2 weeks, by 3 central readers using the Boston Bowel Preparation Score (BBPS), modified BBPS, Harefield Cleansing Scale (HCS), Food and Drug Administration bowel cleansing assessment scale (FDA BCAS), and a 100-mm visual analogue scale (VAS) of bowel cleanliness. Endoscopic activity was assessed with the Simple Endoscopic Score for CD (SES-CD). All assessments were on endoscope insertion and withdrawal and in the ileum, right colon, transverse colon, left colon, and rectum to facilitate evaluation of the relationship between BP and SES-CD scores. Reliability of BP assessment was quantified using the intraclass correlation coefficient (ICC) and interpreted with benchmarks defined by Landis and Koch.1 Validity was assessed by within-patient correlation between each BP scale and the VAS across segments using mixed effect models. Correlation between BP quality and SES-SD scores by location was assessed using Spearman’s rho. Results Substantial (ICC ≥0.61) inter-rater reliability was observed for all BP scales and the VAS during insertion and withdrawal, except for the FDA BCAS, which had moderate (ICC ≥0.41) inter-rater reliability on insertion (Table 1). Intra-rater reliability was similarly substantial for all BP scales and almost perfect (ICC ≥0.81) for the VAS during insertion and withdrawal. Coefficients for the validity of all BP scales based on correlation with the VAS of bowel cleanliness exceeded 0.58 on both insertion and withdrawal. BP and endoscopic disease activity were negatively correlated in the colon, particularly in the left colon, suggesting that lower BP scores in this segment may result in higher SES-CD scores (Table 2). Conclusion Existing scales are reliable for the assessment of BP in patients with CD. These results provide a framework for scoring of BP quality in clinical trials for CD and support the inclusion of patients with CD for the evaluation of novel BP agents. Reference: 1. Landis J.R. and Koch G. G. Biometrics. 1977:33;159-74

gastroenterology & hepatology
Updates in the Management of Crohn's Disease

Sergey Khaitov

DOI: https://doi.org/10.1055/s-0044-1786382

2024-04-27

Clinics in Colon and Rectal Surgery

Abstract:Crohn's disease remains to be a global problem causing significant impact on quality of life of affected patients. It is on the rise, especially in developing countries, and might be related to urbanization and better recognition. It represents a broad spectrum of clinical presentations and severity and unfortunately remains incurable currently despite enormous progress made in recent years in understanding the immunologic basis of this devastating illness. In recent decades tens of new medical agents were developed to influence various steps in immune disarray of Crohn's patients. While most of them prove to be effective and the incidence of surgery needed for mild-to-moderate illness has decreased—still, up to 80% of patients will end up with at least one surgery in their lifetime and many more than once! As mentioned, surgeries will not cure the disease, but they often can provide an effective and fast control of disease symptoms and especially complications. Our surgical enthusiasm will have to be measured against possible surgical complications and sometimes debilitating results of repeated surgeries leading to long-term disabilities like short gut syndrome, permanent ostomies, fecal incontinence. Old principle of medicine stays the same— Primum non nocere ! It became clear that the multifaceted nature of Crohn's disease affects not only the intestinal tract and nearly any system in the body but also patients' minds. Proper management absolutely needs a multidisciplinary approach with gastroenterologists, nutritionists, enterostomal therapists, psychologists. All the specialists should have expertise specifically in management of Crohn's disease—this is best done in settings of specialized Inflammatory Bowel Disease Center. Many centers are organized in major institutions throughout the country. But access to Crohn's specialized tertiary care may be limited. Our goal is to provide support and knowledge from the busiest surgeons and gastroenterologists in the field of Crohn's disease for a broad group of practitioners who will encounter those patients. In this issue of Clinics in Colon and Rectal Surgery , we are trying to touch upon most difficult aspects of this illness related to surgical care ranging from intestinal to anorectal management. We also connected with gastroenterology colleagues to have their input specifically on evolving problems of Crohn's like ileal pouch illness. I am personally blessed to work at the institution where Crohn's history was made at the Mount Sinai Hospital in New York. I hope that with the contribution of our premier authors team we will cover the main difficult issues, which surgeons will encounter in their practice, and this will help improve quality of life and prevent complications in our patients. Sergey Khaitov, MD, FACS, FASCRS Article published online: 25 April 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

gastroenterology & hepatology,surgery
Examining dietary interventions in Crohn's disease

Lynna Chen,Ashish Srinivasan,Abhinav Vasudevan

DOI: https://doi.org/10.3748/wjg.v30.i34.3868

2024-09-14

Abstract:This editorial builds on the article by Shakhshir et al. We conducted an overview of evidence-based dietary interventions in adults with inflammatory bowel disease (IBD). In the IBD population, there may be a role for the Mediterranean diet due to its anti-inflammatory effects, long-term sustainability, and role in improving cardiovascular health. In active Crohn's disease, the use of exclusive enteral nutrition, the Crohn's disease exclusion diet, or the specific carbohydrate diet may be used as a short-term adjunct to medical therapy and may improve mucosal healing. The low-FODMAP diet can assist in reducing symptoms for patients without evidence of active bowel inflammation. As interest in nutritional therapy increases amongst clinicians and patients alike, it is integral that dietary therapies are understood and discussed in routine management of patients with IBD as part of holistic care, ideally through a multidisciplinary setting with involvement of experienced dietitians. This serves to improve clinician-patient engagement and reduce complications of IBD including micro and micronutrient deficiencies.
Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?

Agnes Hiu Yan Ho,Joyce Wing Yan Mak

DOI: https://doi.org/10.1111/apt.18143

IF: 9.524

2024-07-08

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Nordestgaard et al papers. To view these articles, visit https://doi.org/10.1111/apt.18106 and https://doi.org/10.1111/apt.18163

pharmacology & pharmacy,gastroenterology & hepatology
P749 Comparison of bowel preparations for colonoscopy in inflammatory bowel disease- A systematic review and network meta-analysis of randomized trials

A Chatterjee,S Kaur,A Jena,A Patil,U Dutta,S Sebastian,V Sharma

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0879

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Colonoscopy is important in the management inflammatory bowel disease. Adequate bowel preparation (IBD) is a prerequisite for colonoscopy and may be difficult to achieve in setting of IBD Methods We performed a systematic review and network meta-analysis of randomised trials of various bowel preparations used before colonoscopy in IBD. Various electronic databases were searched to identify eligible studies. A frequentist network meta-analysis was done to compare the effectiveness of various bowel preparations. Risk of bias was assessed using Cochrane risk of bias tool 2.0. Other outcomes were assessed qualitatively. Results We included 7 trials including 960 patients. All bowel preparation had a similar effectiveness of bowel preparation as compared to 4 litres of polyethylene glycol (PEG) (OR when compared with PEG4L: OSS- 1.1043 95% CI 0.6553-1.8610; PEG/Ascorbate 2L- 0.9838, 0.6519-1.4848; PEG 1L -1.0011, 0.5522-1.8150; PEG2L plus bisacodyl -1.0864, 0.7130-1.6554; PEG 4L plus simethicone -1.0069, 0.6721-1.5084; PEG/SPMC 1.5L -0.9966, 0.5569-1.7835; SPMC 2L -1.0996, 0.6123-1.9745 had a similar effectiveness. Low-volume preparations had better compliance, tolerance, and acceptance, and willingness to repeat. No difference in additional outcomes like change in disease activity after colonoscopy, procedure-related outcome after colonoscopy like cecal intubation rate, and change in electrolyte levels were found. Conclusion Various bowel preparations had similar effectiveness in respect to colonoscopy preparation in IBD patients. Low-volume preparations have better compliance, tolerance, and acceptance. The systematic review was limited by a small number of included RCTs.

gastroenterology & hepatology
Exploration of an Improved Bowel Preparation for Inflammatory Bowel Disease Patients

Wang Yu,Cao Qian

DOI: https://doi.org/10.3760/cma.j.issn.2096-367x.2018.02.006

2018-01-01

Abstract:Objective To improve the quality of colonoscopy examination by exploring an improved pre-preparation method for patients with inflammatory bowel disease (IBD).Methods A prospective study was carried out.Patients with IBD undergoing colonoscopy at the Center of Inflammatory Bowel Diseases of Sir Run Run Shaw Hospital between December 2016 and March 2017 were divided into control group and trial group according to the order of examination time.The control group received no slag diet 1 day before bowel preparation,and the trial group received no slag diet for breakfast and lunch and oral enteral nutrition solution for dinner.The bowel cleanliness was assessed by the Boston bowel preparation scale (BBPS).Results A total of 114 IBD patients were enrolled with 57 cases in each control and trial group.The BBPS scores in the left hemicolon of both groups were higher than those in the right hemicolon in the same group (control group:2.77 ± 0.54 vs.2.28 ± 0.80,P =0.0002;trial group:2.91 ± 0.28 vs.2.63 ± 0.59,P =0.0015).Compared with control group,trial group had higher BBPS score of right hemicolon (2.63 ± 0.59 vs.2.28 ± 0.80,P =0.009),higher BBPS score of transverse colon (2.98 ±0.13 vs.2.81 ±0.58,P=0.028) and higher total BBPS score (8.53±0.66 vs.7.86± 1.56,P=0.004).There was no statistically significant difference in BBPS score of left hemicolon between two groups.No obvious adverse reactions and complications occurred during the study.Conclusions The bowel preparation cleansing effect of the trial group is better than that of the control group,which is mainly present in right hemicolon and transverse colon.It suggests that for whole colon examination,no slag diet plus oral enteral nutrition solution dinner 1 day before the bowel cleansing will have a better effect,and if for left hemicolon examination only,normal no slag diet 1 day before the bowel cleansing is suitable.
Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?

Tarun Chhibba

DOI: https://doi.org/10.1111/apt.18051

IF: 9.524

2024-06-14

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Norgard et al paper. To view this article, visit https://doi.org/10.1111/apt.18014

pharmacology & pharmacy,gastroenterology & hepatology
Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target

Akhilesh Swaminathan,Andrew S. Day,Miles P. Sparrow,Laurent Peyrin‐Biroulet,Corey A. Siegel,Richard B. Gearry

DOI: https://doi.org/10.1111/apt.18231

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1176-1199, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Cleaning effect and tolerance of 16 bowel preparation regimens on adult patients before colonoscopy: a network meta-analysis

Ming Sun,Guangzhao Yang,Yu Wang

DOI: https://doi.org/10.1007/s00384-023-04355-3

2023-03-11

Abstract:Purpose: Colonoscopy is the gold standard for the diagnosis of colorectal cancer (CRC). Before a colonoscopy, an adequate bowel preparation (BP) is required. Currently, more novel regimens with different effects have been proposed and used successively. This network meta-analysis aims to compare the cleaning effects and patients' tolerability of several BP regimens. Methods: We performed a network meta-analysis of randomized controlled trials including sixteen kinds of BP regimens. We searched PubMed, Cochrane Library, Embase, and Web of Science databases. The outcomes of this study were bowel cleansing effect and tolerance. Results: We included a total of 40 articles with 13,064 patients. For the primary outcomes, polyethylene glycol (PEG) + ascorbic acid (Asc) + simethicone (Sim) (OR, 14.27, 95%CrI, 2.68-127.87) regimen is ranked first in Boston Bowel Preparation Scale (BBPS). PEG + Sim (OR, 2.0, 95%CrI 0.64-6.4) regimen is ranked first in Ottawa Bowel Preparation Scale (OBPS), but without significant differences. For the secondary outcomes, PEG + Sodium Picosulfate/Magnesium Citrate (SP/MC) (OR, 4.88e + 11, 95%CrI, 39.56-1.82e + 35) regimen is the best in cecal intubation rate(CIR). PEG + Sim (OR,1.5, 95%CrI, 1.0-2.2) regimen is ranked first in adenoma detection rate(ADR). Senna (OR, 3.23, 95%CrI, 1.04-9.97) and SP/MC (OR, 249.91, 95%CrI, 78.49-958.19) regimens are ranked first in abdominal pain and willingness to repeat, respectively. There is no significant difference in cecal intubation time (CIT), polyp detection rate (PDR), nausea, vomiting, and abdominal bloat. Conclusion: PEG + Asc + Sim regimen is more effective at cleaning the bowel. PEG + SP/MC will be helpful to increase CIR. For ADR, PEG + Sim regimen will be more helpful. In addition, PEG + Asc + Sim is the least likely to cause abdominal bloat, while Senna regimen is more likely to cause abdominal pain. Patients prefer to re-use the SP/MC regimen for bowel preparation.
Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management

Jakob B. Seidelin

DOI: https://doi.org/10.1111/apt.17964

IF: 9.524

2024-04-11

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 9, Page 1152-1153, May 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus

Andrew H Kim,Charlotte Roberts,Brian G Feagan,Rupa Banerjee,Willem Bemelman,Keith Bodger,Marc Derieppe,Axel Dignass,Richard Driscoll,Ray Fitzpatrick,Janette Gaarentstroom-Lunt,Peter D Higgins,Paulo Gustavo Kotze,Jillian Meissner,Marian O'Connor,Zhi-Hua Ran,Corey A Siegel,Helen Terry,Welmoed K van Deen,C Janneke van der Woude,Alandra Weaver,Suk-Kyun Yang,Bruce E Sands,Séverine Vermeire,Simon Pl Travis

DOI: https://doi.org/10.1093/ecco-jcc/jjx161

2018-03-28

Abstract:Background and aims: Success in delivering value-based healthcare involves measuring outcomes that matter most to patients. Our aim was to develop a minimum Standard Set of patient-centred outcome measures for inflammatory bowel disease [IBD], for use in different healthcare settings. Methods: An international working group [n = 25] representing patients, patient associations, gastroenterologists, surgeons, specialist nurses, IBD registries and patient-reported outcome measure [PROM] methodologists participated in a series of teleconferences incorporating a modified Delphi process. Systematic review of existing literature, registry data, patient focus groups and open review periods were used to reach consensus on a minimum set of standard outcome measures and risk adjustment variables. Similar methodology has been used in 21 other disease areas [www.ichom.org]. Results: A minimum Standard Set of outcomes was developed for patients [aged ≥16] with IBD. Outcome domains included survival and disease control [survival, disease activity/remission, colorectal cancer, anaemia], disutility of care [treatment-related complications], healthcare utilization [IBD-related admissions, emergency room visits] and patient-reported outcomes [including quality of life, nutritional status and impact of fistulae] measured at baseline and at 6 or 12 month intervals. A single PROM [IBD-Control questionnaire] was recommended in the Standard Set and minimum risk adjustment data collected at baseline and annually were included: demographics, basic clinical information and treatment factors. Conclusions: A Standard Set of outcome measures for IBD has been developed based on evidence, patient input and specialist consensus. It provides an international template for meaningful, comparable and easy-to-interpret measures as a step towards achieving value-based healthcare in IBD.
Treat to target in Crohn’s disease: A practical guide for clinicians

Ashish R Srinivasan

DOI: https://doi.org/10.3748/wjg.v30.i1.50

IF: 5.374

2024-01-07

World Journal of Gastroenterology

Abstract:A treat-to-target (T2T) approach applies the principles of early intervention and tight disease control to optimise long-term outcomes in Crohn's disease. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)-II guidelines specify short, intermediate, and long-term treatment goals, documenting specific treatment targets to be achieved at each of these timepoints. Scheduled appraisal of Crohn’s disease activity against pre-defined treatment targets at these timepoints remains central to determining whether current therapy should be continued or modified. Consensus treatment targets in Crohn’s disease comprise combination clinical and patient-reported outcome remission, in conjunction with biomarker normalisation and endoscopic healing. Although the STRIDE-II guidelines endorse the pursuit of endoscopic healing, clinicians must consider that this may not always be appropriate, acceptable, or achievable in all patients. This underscores the need to engage patients at the outset in an effort to personalise care and individualise treatment targets. The use of non-invasive biomarkers such as faecal calprotectin in conjunction with cross-sectional imaging techniques, particularly intestinal ultrasound, holds great promise; as do emerging treatment targets such as transmural healing. Two randomised clinical trials, namely, CALM and STARDUST, have evaluated the efficacy of a T2T approach in achieving endoscopic endpoints in patients with Crohn’s disease. Findings from these studies reflect that patient subgroups and Crohn’s disease characteristics likely to benefit most from a T2T approach, remain to be clarified. Moreover, outside of clinical trials, data pertaining to the real-world effectiveness of a T2T approach remains scare, highlighting the need for pragmatic real-world studies. Despite the obvious promise of a T2T approach, a lack of guidance to support its integration into real-world clinical practice has the potential to limit its uptake. This highlights the need to describe strategies, processes, and models of care capable of supporting the integration and execution of a T2T approach in real-world clinical practice. Hence, this review seeks to examine the current and emerging literature to provide clinicians with practical guidance on how to incorporate the principles of T2T into routine clinical practice for the management of Crohn’s disease.

gastroenterology & hepatology
Editorial: Exclusive enteral nutrition: Positioning in the ever‐growing landscape of inflammatory bowel disease therapy

Krishneel Dutt,Abhinav Vasudevan

DOI: https://doi.org/10.1111/apt.18055

IF: 9.524

2024-05-25

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Plotkin et al papers. To view these articles, visit https://doi.org/10.1111/apt.18028

pharmacology & pharmacy,gastroenterology & hepatology
Editorial: Treatments for inflammatory bowel disease across age‐spectrum—Are they the same? Authors' reply

Mads Damsgaard Wewer,Rie Louise Møller Nordestgaard,Mikkel Malham,Vibeke Wewer,Trine Boysen,Johan Burisch

DOI: https://doi.org/10.1111/apt.18163

IF: 9.524

2024-07-08

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Nordestgaard et al papers. To view these articles, visit https://doi.org/10.1111/apt.18106 and https://doi.org/10.1111/apt.18143

pharmacology & pharmacy,gastroenterology & hepatology
Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease

Marlou P M Adriaanse,Mark Löwenberg,Geert R A M D’Haens

DOI: https://doi.org/10.1080/14712598.2024.2430614

2024-11-27

Expert Opinion on Biological Therapy

Abstract:Introduction Standardized evaluation of endoscopic disease activity using valid, responsive and reliable instruments is crucial for optimizing the efficiency of clinical trials with therapeutic agents for Crohn's disease (CD). Achieving endoscopic remission and/or mucosal healing is associated with improved long-term outcomes, making it an important treatment goal.

medicine, research & experimental,biotechnology & applied microbiology
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras

Daniel Tassone,Imogen Hartley,Nik Sheng Ding

DOI: https://doi.org/10.1111/apt.17861

IF: 9.524

2024-02-15

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 5, Page 713-714, March 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Novel frontiers of agents for bowel cleansing for colonoscopy

Milena Di Leo,Andrea Iannone,Monica Arena,Giuseppe Losurdo,Maria Angela Palamara,Giuseppe Iabichino,Pierluigi Consolo,Maria Rendina,Carmelo Luigiano,Alfredo Di Leo

DOI: https://doi.org/10.3748/wjg.v27.i45.7748

2021-12-07

Abstract:The incidence of colorectal cancer (CRC) is characterized by rapid declines in the wake of widespread screening. Colonoscopy is the gold standard for CRC screening, but its accuracy is related to high quality of bowel preparation (BP). In this review, we aimed to summarized the current strategy to increase bowel cleansing before colonoscopy. Newly bowel cleansing agents were developed with the same efficacy of previous agent but requiring less amount of liquid to improve patients' acceptability. The role of the diet before colonoscopy was also changed, as well the contribution of educational intervention and the use of adjunctive drugs to improve patients' tolerance and/or quality of BP. The review also described BP in special situations, as lower gastrointestinal bleeding, elderly people, patients with chronic kidney disease, patients with inflammatory bowel disease, patients with congestive heart failure, inpatient, patient with previous bowel resection, pregnant/lactating patients. The review underlined the quality of BP should be described using a validate scale in colonoscopy report and it explored the available scales. Finally, the review explored the possible contribution of bowel cleansing in post-colonoscopy syndrome that can be related by a transient alteration of gut microbiota. Moreover, the study underlined several points needed to further investigations.
Fecal calprotectin and endoscopic scores: The cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease

Marcia Henriques de Magalhães Costa,Ligia Yukie Sassaki,Júlio Maria Fonseca Chebli

DOI: https://doi.org/10.3748/wjg.v30.i24.3022

2024-06-28

Abstract:Managing inflammatory bowel disease (IBD) is becoming increasingly complex and personalized, considering the advent of new advanced therapies with distinct mechanisms of action. Achieving mucosal healing (MH) is a pivotal therapeutic goal in IBD management and can prevent IBD progression and reduce flares, hospitalization, surgery, intestinal damage, and colorectal cancer. Employing proactive disease and therapy assessment is essential to achieve better control of intestinal inflammation, even if subclinical, to alter the natural course of IBD. Periodic monitoring of fecal calprotectin (FC) levels and interval endoscopic evaluations are cornerstones for evaluating response/remission to advanced therapies targeting IBD, assessing MH, and detecting subclinical recurrence. Here, we comment on the article by Ishida et al Moreover, this editorial aimed to review the role of FC and endoscopic scores in predicting MH in patients with IBD. Furthermore, we intend to present some evidence on the role of these markers in future targets, such as histological and transmural healing. Additional prospective multicenter studies with a stricter MH criterion, standardized endoscopic and histopathological analyses, and virtual chromoscopy, potentially including artificial intelligence and other biomarkers, are desired.
Compliance with best practice recommendations for colonoscopy bowel preparation among hospitalized patients at a tertiary adult hospital.

Hamid Ullah,Charles C. Chima

DOI: https://doi.org/10.1097/xeb.0000000000000349

2022-10-13

JBI Evidence Implementation

Abstract:INTRODUCTION Proper bowel preparation is essential to successful colonoscopies. The quality of bowel preparation is often poorer in the inpatient settings compared with outpatient settings. This can result in repeat procedures and increased hospital length of stay. OBJECTIVE The aim of this evidence implementation project was to assess and improve compliance with best practice recommendations for bowel preparation prior to colonoscopy. METHODS The project was done in three phases for patients hospitalized at a tertiary adult hospital: the initial audit; clinical practice change that included providing patients with both oral and written education about bowel preparation; and a follow-up audit. RESULTS The baseline audit showed that the hospital was already fully compliant with two out of four best practice criteria. For two criteria with poor compliance rates at baseline, we improved compliance for criterion 1 (giving patients both oral and written education about bowel preparation) from 8 to 40%, while compliance rate for criterion 4 [using 2 l polyethylene glycol - (PEG) or adding ascorbic acid to 4 l PEG] remained at 0% at the end of the intervention. CONCLUSION The JBI evidence implementation program provided a structured approach to analyze colonoscopy bowel preparation practices and develop strategies to align policies with the best practice recommendation of providing written education about bowel preparation. However, there is need for more conclusive evidence to identify the most ideal inpatient bowel preparation formulation.

Medicine

Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales

Performance of bowel preparation quality scales in patients with Crohn's disease

P477 Performance of bowel preparation quality scales in patients with Crohn’s disease

Updates in the Management of Crohn's Disease

Examining dietary interventions in Crohn's disease

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?

P749 Comparison of bowel preparations for colonoscopy in inflammatory bowel disease- A systematic review and network meta-analysis of randomized trials

Exploration of an Improved Bowel Preparation for Inflammatory Bowel Disease Patients

Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?

Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target

Cleaning effect and tolerance of 16 bowel preparation regimens on adult patients before colonoscopy: a network meta-analysis

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus

Treat to target in Crohn’s disease: A practical guide for clinicians

Editorial: Exclusive enteral nutrition: Positioning in the ever‐growing landscape of inflammatory bowel disease therapy

Editorial: Treatments for inflammatory bowel disease across age‐spectrum—Are they the same? Authors' reply

Endoscopic endpoints in biologic clinical trials and beyond: the case for Crohn's Disease

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras

Novel frontiers of agents for bowel cleansing for colonoscopy

Fecal calprotectin and endoscopic scores: The cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease

Compliance with best practice recommendations for colonoscopy bowel preparation among hospitalized patients at a tertiary adult hospital.